Showing 4501-4510 of 5957 results for "".
- First-of-its-Kind Study Finds Artificial Intelligence Screenings Improve Eye Care Access in Sub-Saharan Africahttps://modernod.com/news/first-of-its-kind-study-finds-artificial-intelligence-screenings-improve-eye-care-access-in-sub-saharan-africa/2480906/Orbis announced new research findings demonstrating that diabetic retinopathy screenings supported by artificial intelligence (AI) enhanced patients’ speed and uptake of referral services in Rwanda, which can help reduce vision loss due to diabetes in the region. The study is
- Rayner Acquires Stake in Sustainable Surgical Instrument Belgian Manufacturer Hasa Optixhttps://modernod.com/news/rayner-acquires-stake-in-sustainable-surgical-instrument-belgian-manufacturer-hasa-optix/2480900/Rayner announced that it has entered into a commercial partnership and concurrently acquired a stake in Hasa Optix, a Brussels-based manufacturer of single use ophthalmic surgical instruments and instrument sets. The investment closed June 7, 2022. Financial terms of the deal
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin
- NIH Study Confirms Benefit of Supplements for Slowing AMDhttps://modernod.com/news/nih-study-confirms-benefit-of-supplements-for-slowing-age-related-macular-degeneration-amd/2480894/The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), according to the Nationa
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in
- Apellis Submits New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophyhttps://modernod.com/news/apellis-announces-submission-of-nda-to-the-fda-for-pegcetacoplan-for-geographic-atrophy/2480890/Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base
- AMA: Health Insurance Industry Continues to Falter on Prior Authorization Reformhttps://modernod.com/news/ama-health-insurance-industry-continues-to-falter-on-prior-authorization-reform/2480880/Despite mounting evidence that insurer-imposed authorizations for drugs and medical services can be a hazardous and burdensome administrative obstacle to patient-centered care, the health insurer industry continues to show apathetic or ineffectual follow-through on mutually accepted reforms, acco
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officerhttps://modernod.com/news/visiox-pharma-appoints-ryan-s-bleeks-as-chief-executive-officer/2480872/Visiox Pharma announced the appointment of Ryan S. Bleeks as Chief Executive Officer. "We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's Founding Investor and Executive Chairman. "His